Enduring Material

Shared Management Roundtable
View Activity Info
Enter Basic User Info
View Content
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
National Psoriasis Foundation

6600 SW 92nd Ave., Suite 300
Portland, OR 97223-7195
General Information
Tuesday, January 11, 2022 - Thursday, January 11, 2024
National Psoriasis Foundation
Virtual Conference Room
Shared Management Roundtable
National Psoriasis Foundation
Objectives
  • Describe the known basic science, pathophysiology and psychosocial impact of psoriatic arthritis and be able to appropriately diagnose PsA
  • Employ appropriate strategies to identify risk factors for and treat comorbidities and complex cases associated with psoriatic arthritis
  • Implement the newly released American College of Rheumatology-National Psoriasis Foundation guideline for the treatment of psoriatic arthritis including treat to target goals.
  • Exhibit knowledge of the indications, recommended dosages, efficacy, monitoring and side effects for current psoriatic disease therapies
  • Develop strategies to approach shared psoriatic disease treatment options using collaborative care and appropriate referral
Presentations and Speakers
  • Evan Siegel, MD - Georgetown University School of Medicine
  • Elaine Husni, MD - Cleveland Clinic
  • Joseph Merola, MD - Brigham & Women's Hospital
Available Credits/Points
  • The National Psoriasis Foundation designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Shared Management Roundtable
Disclosure Statements
Speakers:
Elaine Husni, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Amgen - Advisory Committee Member - Relationship Has Not Ended
  • BMS - Advisory Committee Member - Relationship Has Not Ended
  • Lilly - Advisory Committee Member - Relationship Has Not Ended
  • Novartis - Advisory Committee Member - Relationship Has Not Ended
  • Janssen - Advisory Committee Member - Relationship Has Not Ended
  • UCB - Advisory Committee Member - Relationship Has Not Ended
  • PASE - questionnaire royalties - Relationship Has Not Ended
Joseph Merola, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Abbvie, Amgen, Bayer, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi-Regeneron, Biogen, Pfizer, and BMS - Consulting - Relationship Has Not Ended
  • Dermavant, UCB, LEO Pharma, Sanofi, Lilly - Investigator - Relationship Has Not Ended
Evan Siegel, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Eli Lilly & Company - Advisory Committee Member - Relationship Has Not Ended
  • Eli Lilly & Company - Speaking - Relationship Has Not Ended
  • AbbVie - Advisory Committee Member - Relationship Has Not Ended
  • AbbVie - Speaking - Relationship Has Not Ended
  • Horizon - Speaking - Relationship Has Not Ended
  • UCB - Advisory Committee Member - Relationship Has Not Ended
  • UCB - Speaking - Relationship Has Not Ended
  • BMS - Advisory Committee Member - Relationship Has Not Ended

This activity is supported by an educational grant from Pfizer
Accreditation Statement
  • The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
0 %
100 %
1/11/2022
Continue to Enduring Material